Incidence and outcomes of intrapartum-related neonatal encephalopathy in low-income and middle-income countries: a systematic review and meta-analysis

Antti Juhani Kukka, Sara Waheddoost, Nick Brown, Helena Litorp, Johan Wrammert, Ashish KC

ABSTRACT

Aim To examine the incidence of intrapartum-related neonatal encephalopathy, and neonatal mortality and neurodevelopmental outcomes associated with it in low-income and middle-income countries.

Methods Reports were included when neonatal encephalopathy diagnosed clinically within 24 hours of birth in term or near-term infants born after intrapartum hypoxia-ischaemia defined as any of the following: (1) pH≤7.1 or base excess ≤−12 or lactate ≥6, (2) Apgar score ≤5 at 5 or 10 min, (3) continuing resuscitation at 5 or 10 min or (4) no cry from baby at 5 or 10 min. Peer-reviewed articles were searched from Ovid MEDLINE, Cochrane, Web of Science and WHO Global Index Medicus with date limits 1 November 2009 to 17 November 2021. Risk of bias was assessed using modified Newcastle Ottawa Scale. Inverse variance of heterogeneity was used for meta-analyses.

Results There were 53 reports from 51 studies presenting data on 4181 children with intrapartum-related neonatal encephalopathy included in the review. Only five studies had data on incidence, which ranged from 1.5 to 20.3 per 1000 live births. Neonatal mortality was examined in 45 studies and in total 636 of the 3307 (19.2%) infants died. Combined outcome of death or moderate to severe neurodevelopmental disability was reported in 19 studies and occurred in 712 out of 1595 children (44.6%) with follow-up 1 to 3.5 years.

Conclusion Though there has been progress in some regions, incidence, case mortality and morbidity in intrapartum-related neonatal encephalopathy has been static in the last 10 years.

PROSPERO registration number CRD42020177928.

BACKGROUND

Neonatal encephalopathy (NE) is a syndrome of disturbed neurological function presenting during the first days of life.1 Hallmarks of NE include decreased level of consciousness or seizures, difficulty with initiating and maintaining respiration, and altered tone and reflexes.1 Intrapartum-related hypoxia-ischaemia is the most common cause of NE and one of the top three causes of neonatal death globally.3 Nearly half of the survivors of intrapartum-related NE risk neurodevelopmental disability including cerebral palsy (CP), intellectual impairment, deafness and blindness.2 5 These risks are related to the severity of encephalopathy commonly graded as mild, moderate or severe, or grade I, II, III, respectively, based on early neurological examination.1 Intrapartum-related NE is a term primarily used in reference to term and near-term infants.

The most recent systematic review and meta-analysis from 20135 estimated 1.15 million cases of intrapartum-related NE globally per year resulting in 287000 neonatal deaths and 233000 moderate or severe disabilities: 96% occurred in low-income and middle-income countries (LMICs).5 Given global increase in facility deliveries5 and improved neonatal resuscitation6 during the decade that has elapsed since, the situation has likely
changed. Without data, though, the task of the policymakers becomes near impossible. Reducing the burden of intrapartum-related NE is one of the key factors for achieving the Every Newborn Action Plan. We, therefore, conducted a systematic review of intrapartum-related NE in LMICs with the objective of quantifying the following parameters: (1) incidence, (2) neonatal mortality and (3) neurodevelopmental outcomes at follow-up of ≥1 year.

METHODS
Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines were followed and the study protocol was registered beforehand in PROSPERO database (CRD42020177928).

Eligibility criteria
Types of reports
All article types (observational and trial based) providing information on incidence, neonatal mortality or childhood neurodevelopmental outcomes of NE in humans were considered for inclusion. Qualitative studies, reviews, protocols, conference abstracts, editorials and opinion pieces were excluded.

Additional study characteristics
Only data from LMICs classified by World Bank country and lending groups at the median year of data collection were considered. Only reports published after 1 November 2009 were included as this was the last date searched by Lee et al in their previous review and as changes in peripartum care reduce the relevance of older studies. No language restrictions were applied.

Types of study participants
Neonatal encephalopathy
NE was defined clinically as disturbed neurological function diagnosed using criteria proposed by Sarnat and Sarnat or another validated scale within 24 hours of birth. A cut-off of 24 hours was selected to ensure early onset of symptoms commensurate with a hypoxic-ischaemic origin while acknowledging that the symptoms evolve over the first week of life. Due to limited availability in LMICs, electroencephalographic confirmation and neuroimaging were not mandated.

Relation to intrapartum events
Evidence of intrapartum hypoxia-ischaemia was required for inclusion to distinguish from other similar clinical phenotypes. Any of the following parameters was accepted for inclusion:

- Abnormal umbilical cord blood or neonatal blood sample within 1 hour of birth (pH ≤7.1 or base excess ≤−12 or lactate ≥6).
- Apgar score ≤5 at 5 or 10 min.
- Ongoing neonatal resuscitation at 5 or 10 min.
- No cry from baby at 5 or 10 min.

Studies where stated hypoxia-ischaemia criteria were not fully concordant, but sentinel data were provided were discussed and decided case by case.

Gestational age
Gestational age limit was set to ≥35+0 weeks defined by last menstrual period, first trimester ultrasound, fundal height or Ballard score. Lack of data on gestational age or mixing term and preterm infants <35 weeks of gestation in the report led to exclusion of the study to avoid contamination by non-hypoxic-ischaemic preterm brain injury.

Additional exclusion criteria
Studies reporting NE due to other specified causes, such as hyperbilirubinemia, and those where the whole cohort had some specific risk factor such as maternal hypertension rendering the sample non-representative of the normal population were excluded.

Types of outcomes
Reports were included if they included data on one or more of the outcomes below regardless of the original study purpose.

Inclusion criteria for objective 1
Main outcome was incidence of intrapartum-related NE in a birth cohort of a defined size regardless of the denominator used.

Inclusion criteria for objective 2
Main outcome was incidence of mortality in children with intrapartum-related NE either during the neonatal period (first 28 days of life) or until discharge from hospital.

Inclusion criteria for objective 3
Main outcome was incidence of death or moderate to severe disability at follow-up of 1–17 years defined similar to a previous systematic review as any grade of CP, intellectual impairment (IQ ≤2 SD below mean), blindness (vision <6/60 in both eyes), or developmental delay using a validated instrument. In difference to Jacobs et al, any form of deafness was considered and in studies using Bayley Scales of Infant and Toddler Development version II (BSID-II) cut-off of <−2 SD or <70 was used to define moderate to severe disability whereas in BSID-III, <−1 SD or <85 was used for the same as these have been found to be equivalent.

Secondary outcomes were CP, developmental delay assessed with any validated developmental assessment tool, blindness, deafness, epilepsy and neuropsychiatric disorders. Reports without developmental assessment were excluded.

Information sources and search strategy
The following databases were interrogated with the help of a librarian at Uppsala University, Sweden: Ovid MEDLINE, Cochrane, Web of Science and WHO Global
Index Medicus. Search terms related to neonate AND encephalopathy AND LMIC using the Cochrane EPOC LMIC filter version 3 were combined, and the complete searches are presented in online supplemental table 1. This search strategy had not been previously validated. A search was performed for dates 1 November 2009 to 10 June 2020 and this was later updated on 18 November 2021.

Personal records and reference lists of related reviews were hand searched for further publications.11 15–29

Study selection

Records identified were exported to Zotero reference management software (V.5.0.96.3, Roy Rosenzweig Center for History and New Media, Virginia, USA) for removal of duplicates and then transferred to Rayyan (Rayyan Systems, Cambridge, Massachusetts, USA) for blinded screening of title and abstract by two independent reviewers (AJK and SW). Screening questions based on inclusion and exclusion criteria were developed and piloted a priori (online supplemental figure 1). Disagreements were discussed between the two reviewers. Google Translate was used for translation of abstracts when necessary. Full-text articles of records included in the first stage were retrieved and, when not found, the first authors were contacted via email or, when email was not available, via ResearchGate (ResearchGate, Germany) to request access. If no answer was received within 1 month, the article was excluded.

Full-text screening was done similarly using a pre-piloted flow chart (online supplemental figure 2) with results independently recorded on Excel sheets (V.2108, Microsoft, USA). Results were compared and disagreements solved with an arbitrator (NB). Kappa score was calculated to quantify the level of agreement between the reviewers. Reasons for study exclusion in full-text screening stage were recorded in online supplemental table 2). No contact was made with authors to request missing, ambiguous or unprocessed data. If several reports using data from the same study patients were identified, only the report with most complete data was included. Reviewers were not blinded to report authors, institutions or journals. Articles written in languages not understood by the review team were translated into English by people fluent in the language.

Data collection process and data items

Study data were extracted by single reviewer (AJK) on an Excel sheet. Unclear cases were discussed with a second reviewer (NB).

The following background data were recorded: first author and publication year; country/ies; World Bank country income group (low, lower middle or upper middle)9 and national neonatal mortality rate (NMR, low<5/1000, mid 5–15/1000 and high >15/1000 live births)30 at median year of data collection; whether a population- or hospital-based study; level of hospital; study design;case definition of NE; definition of intrapartum hypoxia-ischaemia; gestational age; number of cases classified as mild, moderate and severe NE; sex; type of intervention provided during neonatal period.

In terms of denominator (objective 1), we accepted both term live births and all births during the study period. Numerators for objective 2 were: number of deaths, duration of follow-up and attrition rate and for objective 3: the number of deaths; length of follow-up; attrition rate; definition(s) of abnormal neurodevelopmental outcome(s) and number of children with abnormal outcome(s). Neurodevelopmental outcomes were subcategorised by type when possible.

All outcome data were disaggregated by the severity of intrapartum-related NE when possible.3 Data on intervention and control arms in trials were collected separately. One report could contribute data to several objectives.

Risk of bias in individual studies

Risk of bias was assessed by discussion between two reviewers (AJK and SW) using the Newcastle Ottawa Scale for cohort studies.34 The original tool was modified by removing questions related to comparability of cohorts. The modified version had two questions related to selection of the cohort and three related to outcome assessment with each question awarded maximum one star (table 1, online supplemental table 3).

Synthesis of results

We expected substantial clinical and methodological heterogeneity between the included studies whereby narrative synthesis was prioritised. This included describing the methodological characteristics of each study, their settings and individual strengths and limitations.32 33 Particular attention was paid to comparison of study findings between different geographical and economic contexts.

The three objectives of the review guiding grouping of the reports into tables and figures. Forest plots of the prevalence of main outcomes with point estimate and 95% CIs calculated by Freeman-Tukey double arcsine transformation were presented.34 Inverse variance of heterogeneity model was chosen for meta-analyses as it is suitable for pooling data from heterogeneous studies of varying sizes.35 All analyses were made by using MetaXL V.5.3 (EpiGear International, Sunrise Beach, Queensland, Australia) add-in in Excel. For objective 1, a population-based rather than hospital-based incidence was mandated for meta-analysis due to wide context related variability. For objectives 2 and 3, data were separated by neonatal intervention status and duration of follow-up.

Subgroup analyses by grade of intrapartum-related NE were planned a priori. However, as limited data were available, we combined grades II and III together. Statistical heterogeneity was analysed with I² analysis and >50% considered a sign of high heterogeneity in which case further subgroup analyses post hoc were considered. Sensitivity analysis of stepwise removal of each study
<table>
<thead>
<tr>
<th>Author, reference, year</th>
<th>Country</th>
<th>Study type</th>
<th>Intervention</th>
<th>Cases</th>
<th>NOS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Incidence</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yang, 2019&lt;sup&gt;48&lt;/sup&gt;</td>
<td>China</td>
<td>Cohort</td>
<td>Unclear</td>
<td>262</td>
<td>2+0</td>
</tr>
<tr>
<td><strong>Incidence and neonatal mortality</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Horn, 2013&lt;sup&gt;47&lt;/sup&gt;</td>
<td>South Africa</td>
<td>Retrospective observational</td>
<td>Unclear</td>
<td>110</td>
<td>2+1/1+1</td>
</tr>
<tr>
<td>Moshiro, 2019&lt;sup&gt;39&lt;/sup&gt;</td>
<td>Tanzania</td>
<td>Prospective observational</td>
<td>NT</td>
<td>146</td>
<td>0+1/0+2</td>
</tr>
<tr>
<td>Niaz, 2021&lt;sup&gt;50&lt;/sup&gt;</td>
<td>Pakistan</td>
<td>Prospective observational</td>
<td>Unclear</td>
<td>122†</td>
<td>1+1/0+2</td>
</tr>
<tr>
<td><strong>Incidence, neonatal mortality and developmental outcome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lally, 2014&lt;sup&gt;38&lt;/sup&gt;</td>
<td>India</td>
<td>Prospective observational</td>
<td>TH in 31%</td>
<td>54</td>
<td>0+2/0+2</td>
</tr>
<tr>
<td><strong>Neonatal mortality</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aly, 2015&lt;sup&gt;72&lt;/sup&gt;</td>
<td>Egypt</td>
<td>RCT</td>
<td>TH+Melatonin Vs. TH</td>
<td>30</td>
<td>0+3</td>
</tr>
<tr>
<td>Bharadwaj, 2012&lt;sup&gt;73&lt;/sup&gt;</td>
<td>India</td>
<td>RCT</td>
<td>TH vs NT</td>
<td>130</td>
<td>0+2</td>
</tr>
<tr>
<td>Biselele, 2013&lt;sup&gt;37&lt;/sup&gt;</td>
<td>Congo DR</td>
<td>Prospective observational</td>
<td>NT</td>
<td>44</td>
<td>0+2</td>
</tr>
<tr>
<td>Biselele, 2020&lt;sup&gt;74&lt;/sup&gt;</td>
<td>Congo Dr</td>
<td>Pilot/case-series</td>
<td>2-iminobiotin</td>
<td>7</td>
<td>0+2</td>
</tr>
<tr>
<td>Biselele, 2018&lt;sup&gt;45&lt;/sup&gt;</td>
<td>Congo Dr</td>
<td>Prospective observational</td>
<td>NT</td>
<td>57</td>
<td>1+2</td>
</tr>
<tr>
<td>Biselele, 2014&lt;sup&gt;57&lt;/sup&gt;</td>
<td>Congo Dr</td>
<td>Prospective observational</td>
<td>NT</td>
<td>19</td>
<td>0+1</td>
</tr>
<tr>
<td>Bozkurt, 2021&lt;sup&gt;75&lt;/sup&gt;</td>
<td>Turkey</td>
<td>Retrospective observational</td>
<td>TH</td>
<td>166</td>
<td>0+1</td>
</tr>
<tr>
<td>El Shimi, 2014&lt;sup&gt;51&lt;/sup&gt;</td>
<td>Egypt</td>
<td>RCT</td>
<td>EPO vs TH vs NT</td>
<td>30</td>
<td>0+2</td>
</tr>
<tr>
<td>Enweronu–Laryea, 2019&lt;sup&gt;34&lt;/sup&gt;</td>
<td>Ghana</td>
<td>Cohort</td>
<td>Passive TH</td>
<td>13</td>
<td>1+1</td>
</tr>
<tr>
<td>Hassanein, 2017&lt;sup&gt;55&lt;/sup&gt;</td>
<td>Egypt</td>
<td>Case-Control</td>
<td>Unclear</td>
<td>20</td>
<td>0+1</td>
</tr>
<tr>
<td>Horn, 2010&lt;sup&gt;52&lt;/sup&gt;</td>
<td>South Africa</td>
<td>Case Series</td>
<td>TH</td>
<td>5</td>
<td>0+2</td>
</tr>
<tr>
<td>Horn, 2012&lt;sup&gt;76&lt;/sup&gt;</td>
<td>South Africa</td>
<td>Case Series</td>
<td>TH</td>
<td>14</td>
<td>0+2</td>
</tr>
<tr>
<td>Kinoshita, 2021&lt;sup&gt;77&lt;/sup&gt;</td>
<td>Brazil</td>
<td>Retrospective observational</td>
<td>TH (FGP)</td>
<td>71</td>
<td>0+1</td>
</tr>
<tr>
<td>Martinez-Hernández, 2020&lt;sup&gt;78&lt;/sup&gt;</td>
<td>Mexico</td>
<td>Before-After Study</td>
<td>EPO+TH (WBC vs SHC)</td>
<td>12</td>
<td>0+1</td>
</tr>
<tr>
<td>Oliveira, 2018&lt;sup&gt;79&lt;/sup&gt;</td>
<td>India</td>
<td>Prospective observational</td>
<td>TH</td>
<td>82</td>
<td>0+2</td>
</tr>
<tr>
<td>Surmeli Onay, 2021&lt;sup&gt;80&lt;/sup&gt;</td>
<td>Turkey</td>
<td>Before-After Study</td>
<td>TH vs TH+Aminophylline</td>
<td>34</td>
<td>0+0</td>
</tr>
<tr>
<td>Prashantha, 2019&lt;sup&gt;81&lt;/sup&gt;</td>
<td>India</td>
<td>Before-After Study</td>
<td>TH (PCM vs FGP)</td>
<td>62</td>
<td>0+1</td>
</tr>
<tr>
<td>Shabeer‡§, 2017&lt;sup&gt;82&lt;/sup&gt;</td>
<td>India</td>
<td>Before-After Study</td>
<td>TH (PCM vs FGP)</td>
<td>68</td>
<td>0+1</td>
</tr>
<tr>
<td>Shrestha, 2020&lt;sup&gt;83&lt;/sup&gt;</td>
<td>Nepal</td>
<td>Prospective observational</td>
<td>NT</td>
<td>20¶</td>
<td>0+1</td>
</tr>
<tr>
<td>Tanigasalam, 2016&lt;sup&gt;84&lt;/sup&gt;</td>
<td>India</td>
<td>RCT</td>
<td>TH (FGP) vs NT</td>
<td>120</td>
<td>0+2</td>
</tr>
<tr>
<td>Thomas,** 2018&lt;sup&gt;84&lt;/sup&gt;</td>
<td>India</td>
<td>Prospective observational</td>
<td>TH (PCM)</td>
<td>103</td>
<td>0+1</td>
</tr>
<tr>
<td>Umran, 2016&lt;sup&gt;85&lt;/sup&gt;</td>
<td>Iraq</td>
<td>Case- Control</td>
<td>NT</td>
<td>29</td>
<td>0+1</td>
</tr>
<tr>
<td>Variane, 2017&lt;sup&gt;85&lt;/sup&gt;</td>
<td>Brazil</td>
<td>Prospective observational</td>
<td>TH</td>
<td>17</td>
<td>0+0</td>
</tr>
<tr>
<td>Yang and Li, 2020&lt;sup&gt;86&lt;/sup&gt;</td>
<td>China</td>
<td>RCT</td>
<td>TH (48hours) vs TH (72hours) vs NT</td>
<td>92</td>
<td>0+2</td>
</tr>
<tr>
<td><strong>Neonatal mortality and developmental outcome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aker,‡ 2021&lt;sup&gt;87&lt;/sup&gt;</td>
<td>India</td>
<td>RCT</td>
<td>TH (PCM) vs NT</td>
<td>49</td>
<td>0+3+0</td>
</tr>
<tr>
<td>Catherine,**†† 2021&lt;sup&gt;88&lt;/sup&gt;</td>
<td>India</td>
<td>RCT</td>
<td>TH (PCM) vs NT</td>
<td>158</td>
<td>0+1+3</td>
</tr>
<tr>
<td>Catherine,**†† 2020&lt;sup&gt;89&lt;/sup&gt;</td>
<td>India</td>
<td>RCT</td>
<td>TH (PCM) vs NT</td>
<td>158</td>
<td>0+1+3</td>
</tr>
<tr>
<td>Celik,‡‡, 2015&lt;sup&gt;90&lt;/sup&gt;</td>
<td>Turkey</td>
<td>RCT</td>
<td>TH SHC vs WBC</td>
<td>7</td>
<td>0+2+3</td>
</tr>
<tr>
<td>Celik,‡‡, 2016&lt;sup&gt;90&lt;/sup&gt;</td>
<td>Turkey</td>
<td>RCT</td>
<td>TH SHC vs WBC</td>
<td>29</td>
<td>0+2+3</td>
</tr>
<tr>
<td>Das, 2017&lt;sup&gt;91&lt;/sup&gt;</td>
<td>India</td>
<td>RCT</td>
<td>TH (FGP) vs NT</td>
<td>60</td>
<td>0+3+3</td>
</tr>
<tr>
<td>Gucuyener, 2012&lt;sup&gt;60&lt;/sup&gt;</td>
<td>Turkey</td>
<td>Case Series</td>
<td>TH</td>
<td>10</td>
<td>0+3+2</td>
</tr>
</tbody>
</table>

Continued
were done for all estimates to see if any single study was inflicting disproportionate effect on the results.

**Risk of bias across studies**

A funnel plot of studies included for the forest plots was examined as an indication of potential publication bias.36

**Patient and public involvement**

No patients were involved in the design and conduct of this study.

**RESULTS**

**Study selection**

The final search produced 1750 records and after removing 417 duplicates and 11 reports published prior to November 2009, 1322 unique reports remained (figure 1). All articles included an abstract in English. There were 121 cases of conflicts between the reviewers during title and abstract screening, which were solved by discussion. The 269 reports identified were sought for retrieval and complemented by 104 reports found from other sources.

Screening of full text resulted in 53 reports from 51 studies being included in the review. There were 35 cases of conflict between the reviewers, which were solved by arbitration (88.2% agreement, Cohen’s kappa=0.55, moderate agreement). Translation into English was done for 13 reports (8 from Chinese, 2 from Turkish and 1 from Russian). Reasons for excluding reports in the full-text screening stage are presented in online supplemental table 2.

**Study characteristics**

Characteristics of the included reports are presented in table 1. The studies included 4181 children with intrapartum-related NE. When looking at only those nine

<table>
<thead>
<tr>
<th>Author, reference, year</th>
<th>Country</th>
<th>Study type</th>
<th>Intervention</th>
<th>Cases</th>
<th>NOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jia, 201841</td>
<td>China</td>
<td>Non-random trial</td>
<td>TH early vs TH late vs NT</td>
<td>152</td>
<td>0+2+2</td>
</tr>
<tr>
<td>Khwuthyakorn, 202192</td>
<td>Thailand</td>
<td>Observational</td>
<td>TH</td>
<td>23</td>
<td>0+1+3</td>
</tr>
<tr>
<td>Malla, 201759</td>
<td>India</td>
<td>RCT</td>
<td>EPO vs NT</td>
<td>100</td>
<td>1+3+3</td>
</tr>
<tr>
<td>Msaoulineine, 201749</td>
<td>Morocco</td>
<td>Non-random comparison</td>
<td>TH 50%, NT 50%</td>
<td>38</td>
<td>1+1+1</td>
</tr>
<tr>
<td>Perez, 201883</td>
<td>Brazil</td>
<td>Cohort</td>
<td>TH (LFU)</td>
<td>53</td>
<td>0+1+3</td>
</tr>
<tr>
<td>Procianoy, 202084</td>
<td>Brazil</td>
<td>Prospective observational</td>
<td>TH</td>
<td>72</td>
<td>0+2+3</td>
</tr>
<tr>
<td>Sun, 201244</td>
<td>China</td>
<td>RCT</td>
<td>TH vs NT</td>
<td>51</td>
<td>1+3+3</td>
</tr>
<tr>
<td>Thayyil, 202146</td>
<td>3 Countries</td>
<td>RCT</td>
<td>TH vs NT</td>
<td>408</td>
<td>1+1+2</td>
</tr>
<tr>
<td>Valera, 201586</td>
<td>Argentina</td>
<td>Observational</td>
<td>TH</td>
<td>27</td>
<td>0+3+3</td>
</tr>
<tr>
<td>Zhou,§ 201062</td>
<td>China</td>
<td>RCT</td>
<td>TH vs NT</td>
<td>194</td>
<td>1+1+2</td>
</tr>
<tr>
<td>Zhu, 200996</td>
<td>China</td>
<td>RCT</td>
<td>EPO vs NT</td>
<td>167</td>
<td>1+2+2</td>
</tr>
<tr>
<td>Zou,§ 201943</td>
<td>China</td>
<td>RCT</td>
<td>TH vs NT</td>
<td>99</td>
<td>1+2+3</td>
</tr>
</tbody>
</table>

Developmental outcome

MAX 2+3
studies that recruited and reported all NE grades indiscriminately, the distribution of severity was 334/858 (38.9%) mild, 292/858 (34.0%) moderate and 232/858 (27.0%) severe NE. Sex of the newborn was reported in 38 studies and pooled prevalence of male sex was 63% (95% CI 58% to 69%, I²=80%) (online supplemental figure 3).

The studies included data from 18 countries with 14 reports from Africa, 6 from Americas, 34 from Asia and none from Oceania or Europe with Turkey classified as part of Asia. Low-income countries were presented in 5 reports, lower-middle in 23 reports and upper-middle-income countries in 25 reports. National NMR was low in 1, medium in 24 and high in 27 reports at the time of data collection. One study presented data from both a low NMR setting (Sri Lanka) and high mortality settings (Bangladesh and India) (online supplemental table 4).

The vast majority (45/51) of studies were conducted in either university or tertiary hospitals and only two studies from China and South Africa, respectively, claimed to be population-based. Inclusion criteria used in the individual studies varied widely and are presented in online supplemental table 4. Therapeutic hypothermia was routinely used in 21 and trialled in 18 of the 53 reports.

Bias evaluation of the included studies

Results of the risk of bias evaluation are presented in table 1 and online supplemental table 3. No report achieved full scores. Major shortcomings were identified in the representativeness of the data with only three papers scoring a star in this question. Reports about neonatal mortality and developmental outcomes had better scores for case ascertainment than those where incidence of intrapartum-related NE was examined. About half of the reports had issues with incomplete follow-up, which might further bias the results.

No obvious asymmetry implying publication bias was observed in the funnel plots presented in online supplemental figures 4 and 5, but the results were scattered due to high heterogeneity.

Results of individual studies and syntheses

Studies reporting incidence

Data on incidence of intrapartum-related NE are presented in table 2. Incidence of all grade NE ranged from 20.3/1000 live births to 1.5/1000 term live births depending on study setting and location (median 4.7/1000 live births, five studies). Only two population-based studies were included whereby no meta-analysis was conducted. One was examining different definitions of intrapartum-related NE in Cape Town, South Africa, and in this paper the incidence of any grade NE ranged from 2.3 to 4.3 per 1000 live births. The second presented data from 27 hospitals in China with incidence of any grade of NE 1.5 per 1000 live births.
The hospital-based studies on incidence came from India, Pakistan, and Tanzania, all of which had high national NMR at the time of data collection.

Studies reporting neonatal mortality
Neonatal mortality associated with intrapartum-related NE was reported in 45 studies (online supplemental table 5). In total, 636 of the 3307 (19.2%) included neonates died. Mortality ranged from 19/30 (63.3%) in a small Egyptian trial comparing conventional care with therapeutic hypothermia and erythropoietin to 0/5 in a case series of therapeutic hypothermia in South Africa and 1/51 (2.0%) in a cooling trial in a tertiary centre in China.

There were limited data available for neonatal mortality disaggregated by severity of NE. Only 10 reports included data on mortality associated with grade I intrapartum-related NE. Only three studies provided data on outcomes of children with mild NE. None of the seven children treated with normothermia in Turkey had death or moderate to severe disability at 12 months’ age. In a therapeutic hypothermia trial in China, 6 out of 19 cooled and 7 out of 15 normothermic infants had moderate intellectual disability (Gesell Child Development Age Scale 70–84) at 18 months’ age while none died or had severe disability. A cohort study from South Africa reported that 1 out of 14 infants with mild NE developed CP at follow-up of mean 14.3 months.

Figure 2 shows the combined outcome of death or moderate to severe developmental disability in children with grade II or III intrapartum-related NE from 16 studies where these data could be extracted. All these studies were either intervention trials or used therapeutic hypothermia as part of routine care and the results are split by intervention status and duration of follow-up. Children in conventional care group had somewhat higher incidence of the combined outcome than those in the intervention group at 1–2 years’ follow-up (32% (95% CI 44% to 66%, I²=61%, 7 studies) vs 40% (95% CI 29% to 52%, I²=84%, 13 studies)). Only three studies had follow-up longer than two or more years. No single study had overwhelming impact in the results in a sensitivity analysis.

Studies reporting neurodevelopmental outcome
Neurodevelopmental follow-up of at least 1 year was conducted in 23 studies (online supplemental table 6). No studies continued follow-up beyond 3.5 years precluding inference on neuropsychiatric conditions. A combined outcome of death or moderate to severe neurodevelopmental disability was reported in 19 studies with 1595 children with any grade of NE of whom 712 (44.6%) had adverse outcome.

Figure 3 shows the combined outcome of death or moderate to severe developmental disability in children with grade II or III intrapartum-related NE from 16 studies where these data could be extracted. All these studies were either intervention trials or used therapeutic hypothermia as part of routine care and the results are split by intervention status and duration of follow-up. Children in conventional care group had somewhat higher incidence of the combined outcome than those in the intervention group at 1–2 years’ follow-up (32% (95% CI 44% to 66%, I²=61%, 7 studies) vs 40% (95% CI 29% to 52%, I²=84%, 13 studies)). Only three studies had follow-up longer than two or more years. No single study had overwhelming impact in the results in a sensitivity analysis.

<table>
<thead>
<tr>
<th>Author (ref)</th>
<th>Country</th>
<th>Definition of denominator</th>
<th>Reported incidence</th>
<th>Incidence/1000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Horn, 2013</td>
<td>South Africa</td>
<td>All live births (incl. home births)</td>
<td>All grades</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Grade I</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Grades II–III</td>
<td>N/A</td>
</tr>
<tr>
<td>Lally, 2014</td>
<td>India</td>
<td>All births in the hospital</td>
<td>All grades</td>
<td>54/11 532</td>
</tr>
<tr>
<td>Moshiro, 2019</td>
<td>Tanzania</td>
<td>All live births in the hospital</td>
<td>All grades</td>
<td>146/10 320</td>
</tr>
<tr>
<td>Niaz, 2021</td>
<td>Pakistan</td>
<td>All births in the hospital</td>
<td>All grades</td>
<td>122/5986</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Grade I</td>
<td>61/5986</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Grade II</td>
<td>42/5986</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Grade III</td>
<td>19/5986</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Grades II–III</td>
<td>61/5986</td>
</tr>
<tr>
<td>Yang, 2019</td>
<td>China</td>
<td>Term live births in the 27 hospitals</td>
<td>All grades</td>
<td>262/175 223</td>
</tr>
</tbody>
</table>

N/A, Not Available.
CP in survivors was evaluated in 11 reports (914 children, mean incidence 16.7%, online supplemental table 6 and online supplemental figure 7). In infants surviving grades II–III intrapartum-related NE, incidence of CP ranged from 29/84 (34.5%) at mean age of 19 months in another Indian cohort where one-third of the children were treated with hypothermia. In one Turkish case series, none of the three children surviving therapeutic hypothermia treatment had CP by the age of 12 months.

**DISCUSSION**

This systematic review identified 53 reports from 51 studies reinforcing the scale of intrapartum-related NE in terms of burden of disease, death and disability in LMICs.

Estimates of NE incidence ranged from 1.5 to 20.3/1000 births comparable to 2013 review by Lee et al.3 A study from China reported low NE incidence at 1.5/1000 term live births6 resembling levels seen in high-income countries with low NMR. Low incidence combined with excellent outcomes reported in other studies included in the review is in line with recent Global Burden of Disease data indicating that the burden of NE in China is rapidly decreasing with the rider that assessment bias cannot be ruled out in the register based incidence study. NE-related neonatal mortality and adverse neurodevelopmental outcome were associated with all grades of intrapartum-related NE. There was scarcity of data on combined grades II–III intrapartum-related NE produced the most comparable outcomes. Similar to Lee et al,6 the highest mortality was
seen in studies from high national NMR settings when no neuroprotective interventions during the newborn period were provided (pooled mortality 32% (95% CI 16% to 49%) vs 28% (95% CI 19% to 37%) reported by Lee et al.\textsuperscript{6}).

The combined outcome of death or moderate to severe neurodevelopmental disability occurred on average at similar rate as in the original cooling trials, where its pooled incidence was 31.7% in the intervention arm and 61.4% in the control group.\textsuperscript{11} Overall, our review showed better outcomes in studies where infants received therapeutically hypothermia or other neuroprotective interventions during neonatal period, but the pooled results in figures are not comparable as different studies were included in each group. This area is currently highly controversial in the light of the HELIX multicentre trial where cooling was predictive of a significantly neonatal higher mortality,\textsuperscript{46} the interpretation of which is causing difficulty for institutions and policy makers. Several meta-analyses with conflicting results have been recently published on efficacy of therapeutic hypothermia in LMICs.\textsuperscript{16-63,66}

Though we cannot extrapolate from the data exactly which single interventions will have the greatest impact on neonatal and childhood neurodevelopmental outcomes, it is likely, that a combined approach including improved antenatal care, adolescent health, family planning and access to hospital delivery centres rather than a silo-driven policy will be required to reduce the disease burden.\textsuperscript{7}

Strengths

Our review has several strengths, including up-to-date data, PRISMA adherence, clear a priori assessment processes and a wide geographical spread of studies.

Limitations

NE is a challenging diagnosis and only a minority of papers reported standardisation of the criteria. We cannot be sure that all the infants fulfilling the inclusion criteria were true cases of intrapartum-related NE, but tried to minimise this by only including studies where intrapartum hypoxia-ischaemia could be presumed with a high degree of certainty. Indirectly, this led to exclusion of studies from lower levels of care with limited access to physicians trained in NE assessment. Remaining heterogeneity in inclusion criteria of individual studies partly explains the wide differences in the reported outcomes.

Only two of the included studies were population-denominator based and the substantial heterogeneity in outcomes is likely to reflect both true variance between populations and methodological differences. The meta-analysis results should, therefore, be interpreted with caution. The preponderance of intervention studies from tertiary level referral hospitals from middle-income countries is likely to have further limited generalisability, but on the other hand use of therapeutic hypothermia is already widespread in such settings.\textsuperscript{67-70} Further limitation on interpretation of the forest plots is that the Freeman Tukey back-transformation is prone to producing misleading results when sample sizes vary greatly, but we did not observe such issue in our data.\textsuperscript{71}

Lastly, although we conducted a systemic search of databases, 12 of the 53 included articles were identified from other sources indicating that the search terms used were not optimal and potential articles might have been missed. The Cochrane EPOC LMIC filter has not been validated and NE has no MeSH term whereby terms related to hypoxia-ischaemia were used instead. Chinese language databases and grey literature were not searched.

CONCLUSION

Though there has been progress in some regions, the incidence, neonatal mortality and morbidity of intrapartum-related NE has in most LMICs been static in the 10 years since the last review.

Twitter Ashish KC @Ashish_K_C

Acknowledgements Authors would like to thank Uppsala University librarian Kazuko Gustafsson for conducting the literature searches, and Melissa Öztürk, Haqing Gao and Otto Haapsamo for translation of articles.

Contributors AJK, AKC, HL, JW and NB conceptualised and designed the study. AJK, NB and SW collected and interpreted the data. AKC drafted the work and all authors revised it critically, approved the final version and agree to be accountable for all aspects of the work. AKC is responsible for the overall content as the guarantor and accept full responsibility for the finished work and the conduct of the study, had access to the data, and controlled the decision to publish.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study is a review of already published research and no ethical permit was sought for its conduct.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplemental information. All data extracted from the articles for the analyses presented in this review are available in online supplemental tables.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Antti Juhani Kukka http://orcid.org/0000-0002-5879-7417
Helena Litorp http://orcid.org/0000-0001-7164-598X
Ashish KC http://orcid.org/0000-0002-0541-4486


7 Lavin JE, Blencowe H, Oza S, et al. Every newborn: progress, priorities, and potential beyond survival. Lancet 2021;398:870–905.


Correction: Incidence and outcomes of intrapartum-related neonatal encephalopathy in low-income and middle-income countries: a systematic review and meta-analysis


In the published version the data in figure 3D and online supplemental table 6 is incorrect. The study by Khuwuthyakorn 2021 (78) was accidentally included in the figure 3D presenting combined outcome of death or moderate to severe disability at follow-up despite only reporting death or severe disability. Please refer to the revised figure 3 mentioned below and revised online supplemental table 6 linked to the paper.

Figure 3
This change will also result in correction in the Abstract’s Result section and paragraph regarding ‘Studies reporting neurodevelopmental outcome’ on the pg 7 of the published article:

**Results**

There were 53 reports from 51 studies presenting data on 4181 children with intrapartum-related neonatal encephalopathy included in the review. Only five studies had data on incidence, which ranged from 1.5 to 20.3 per 1000 live births. Neonatal mortality was examined in 45 studies and in total 636 of the 3307 (19.2%) infants died. Combined outcome of death or moderate to severe neurodevelopmental disability was reported in 18 studies and occurred in 695 out of 1575 children (44.1%) with follow-up 1 to 3.5 years.

**Studies reporting neurodevelopmental outcome**

Neurodevelopmental follow-up of at least 1 year was conducted in 23 studies (online supplemental table 6). No studies continued follow-up beyond 3.5 years precluding inference on neuropsychiatric conditions. A combined outcome of death or moderate to severe neurodevelopmental disability was reported in 18 studies with 1575 children with any grade of NE of whom 695 (44.1%) had adverse outcome.

Only three studies provided data on outcomes of children with mild NE. None of the seven children treated with normothermia in Turkey had death or moderate to severe disability at 12 months’ age. In a therapeutic hypothermia trial in China, 6 out of 19 cooled and 7 out of 15 normothermic infants had moderate intellectual disability (Gesell Child Development Age Scale 70–84) at 18 months’ age while none died or had severe disability. A cohort study from South Africa reported that 1 out of 14 infants with mild NE developed CP at follow-up of mean 14.3 months.

Figure 3 shows the combined outcome of death or moderate to severe developmental disability in children with Grade II or III intrapartum-related NE from 15 studies where this data could be extracted. All these studies were either intervention trials or used therapeutic hypothermia as part of routine care and the results are split by intervention status and duration of follow-up. Children in conventional care group had somewhat higher incidence of the combined outcome than those in the intervention group at 1–2 years’ follow-up (52% (95% CI 44 to 66%, I2 61%, 7 studies) vs 40% (95% CI 29 to 52%, I2=84%, 13 studies)). Only two studies had follow-up longer than that. No single study had overwhelming impact in the results in a sensitivity analysis.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.